REG - Yourgene Health PLC - Directorate Change

Yourgene HealthAnnouncement

26/04/2022 07:16

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220426:nRSZ2804Ja&default-theme=true

RNS Number : 2804J  Yourgene Health PLC  26 April 2022

 

Yourgene Health plc

("Yourgene", "Group", or the "Company")

 

Directorate Change

 

Manchester, UK - 26 April 2022: Yourgene (AIM: YGEN), a leading international
molecular diagnostics group, announces that after a five-year tenure, Adam
Reynolds will step down from his position as Chairman, at the Company's next
Annual General Meeting ("AGM"). The Board is pleased to confirm that he will
remain on the Board as a Non-executive Director.

 

Dr John Brown CBE, currently a Non-executive Director of the Company and its
Senior Independent Director, will assume the role of Chairman of the Group
from the same date.

 

Adam Reynolds has been instrumental in transforming the Company in his five
years of service as Chairman, and before that as a Non-executive Director,
overseeing key hires on the senior leadership team, rebuilding and navigating
the Company post litigation and guiding Yourgene through several successful
acquisitions, all contributing to the Group recording record revenue growth,
sustaining a step change in financial performance and creating a broader
offering of products and services. In the coming months Adam will ensure an
orderly handover and transition to a Non-executive Director role.

 

Dr John Brown joined the Board of Yourgene on 29 July 2019 as a Non-executive
Director and has acted as Senior Independent Director to the Company. Dr Brown
has over 20 years' capital markets experience in the healthcare and life
sciences sector. He is currently a Senior Independent Director of Acacia
Pharma and is Chairman of Calcivis. Additionally, he has previous significant
board experience with roles including Chairman of Axis-Shield, BTG and Cell
Therapy Catapult, Non-executive Director of Vectura and Chief Executive
Officer of Acambis.

 

Adam Reynolds, outgoing Chairman of Yourgene, said: "As we embark on the next
phase of Yourgene's journey  we have a very strong successor in Dr  John
Brown as Chairman. I will remain on the Board as a supportive NED and
shareholder and I remain as convinced as ever in the prospects for Yourgene
Health."

 

Lyn Rees, CEO of Yourgene, said: "I would like to thank Adam for his support
and contribution to Yourgene, as the Group has transformed into the business
it is today. Adam has been instrumental in overseeing the growth we have
achieved and we are pleased that we can retain his extensive experience and
knowledge as he remains a supportive NED.

 

"We are thrilled Dr John Brown is becoming the Group's Chairman, a testament
to Yourgene attracting such a high calibre and experienced Chair, who has been
able to get to know the business over the last couple of years whilst in his
current NED role. The breadth of capital markets experience in the healthcare
sector Dr Brown can offer Yourgene is paramount as the Group enters its next
stage of growth and development."

 

This announcement contains inside information for the purposes of the UK
Market Abuse Regulation.

The Directors of the Company take responsibility for this announcement.

 

 Yourgene Health plc                                Tel: +44 (0)161 669 8122

 Lyn Rees, Chief Executive Officer                  investors@yourgene-health.com (mailto:investors@yourgene-health.com)
 Barry Hextall, Chief Financial Officer
 Joanne Cross, Director of Marketing

 Cairn Financial Advisers LLP (NOMAD)               Tel: +44 (0)20 7213 0880
 Liam Murray / James Caithie / Ludovico Lazzaretti

 Singer Capital Markets (Joint Corporate Broker)    Tel: +44 (0)20 7496 3000
 Aubrey Powell / Tom Salvesen / George Tzimas

 Stifel Nicolaus Europe Limited (Joint Corporate Broker)                                   Tel: +44 (0)20 7710 7600
 Nicholas Moore / Matthew Blawat / Ben Maddison

 Walbrook PR Ltd (Media and Investor Relations)     Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
 Paul McManus / Lianne Applegarth / Alice Woodings  Mob: 07980 541 893 / Mob: 07584 391 303 /

                                                    Mob: 07407 804 654

 

 

About Yourgene Health

 

Yourgene Health is an international molecular diagnostics group which develops
and commercialises genetic products and services. The group works in
partnership with global leaders in DNA technology to advance diagnostic
science.

 

Yourgene primarily develops, manufactures, and commercialises simple and
accurate molecular diagnostic solutions, for reproductive health, precision
medicine and now infectious diseases. The Group's flagship products include
non-invasive prenatal tests (NIPT) for Down Syndrome and other genetic
disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests,
and a recent extension into the oncology space with DPYD genotyping.

 

The launch of Yourgene Genomic Services has enabled Yourgene to offer a global
laboratory service network equipped to be a full life-cycle partner for
clinical, research and pharmaceutical organisations to support partners at the
preclinical, clinical, and post-market stages to develop, manufacture, obtain
regulatory approval and commercialise new products and services. In addition,
Yourgene Genomic Services offers an NIPT and high throughput COVID testing
service.

 

In August 2020, Yourgene acquired Coastal Genomics, Inc., a sample preparation
technology company based in Vancouver, Canada, enabling the Company to extend
its offering and IP portfolio in the DNA sample preparation sector. The
acquisition increased Yourgene's geographical penetration into the US and
Canada, supplementing existing coverage in the UK, Europe, MEA and Asia.

 

Yourgene Health is headquartered in Manchester, UK with offices in Taipei,
Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM
market under the ticker "YGEN". For more information visit
www.yourgene-health.com (http://www.yourgene-health.com/) and follow us on
twitter @Yourgene_Health.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAZZGZDLKZGZZM